MERIDIAN, Idaho, Jan. 8 /PRNewswire-FirstCall/ -- RxElite, Inc. (OTC Bulletin Board: RXEI), a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that as permitted under the registration rights agreement, it has voluntarily instructed all named selling stockholders to cease using the company's Registration Statement on Form SB-2 (File No. 333-146641) and January 3, 2008 prospectus until further advised. This release corrects and should replace the release of January 4, 2008 in its entirety. Once conditions permit reliance on the prospectus included in the Registration Statement, the company will notify selling stockholders.
This notice is provided for informational purposes only, and does not represent a solicitation or offer to buy or sell any security. Any offer will be made my means of a current prospectus only. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About RxElite, Inc.
RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 involving
known and unknown risks, delays, and uncertainties that may cause our
actual results or performance to differ materially from those expressed or
implied by these forward-looking statements. These risks, delays, and
uncertainties include, but are not limited to: risks associated with the
uncertainty of future financial results, our reliance on our sole supplier,
the limited diversification of our product offerings, additional financing
requirements, development of new products, government approval processes,
the impact of competitive products or pricing, technological changes, the
effect of economic conditions and other uncertainties detailed in the
Company's filings with the Securities and Exchange Commission. The Company
undertakes no obligation to update any forward-looking statements.
Corporate Information Investor Relations
Ph: (208) 288-5550 Charlie Forshee, 215-885-4981
Toll Free: (800) 414-1901 firstname.lastname@example.org
Fax: (208) 288-1191 Segue Ventures LLC
|SOURCE RxElite, Inc.|
Copyright©2008 PR Newswire.
All rights reserved